Ultragenyx Pharmaceutical Inc. (RARE) Stock
RARE Key Statistics
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.
CEO: Emil D. Kakkis. Company website
RARE — Frequently Asked Questions
What is the RARE stock price today?
Ultragenyx Pharmaceutical Inc. (RARE) trades at $16.70, up 3.47% on the day, as of Nov 12, 2026 09:31 UTC.
What is Ultragenyx Pharmaceutical Inc.'s market cap?
Ultragenyx Pharmaceutical Inc. has a market capitalisation of $1.65B, calculated from the live RARE share price and shares outstanding.
What is the P/E ratio of RARE?
RARE has no meaningful price-to-earnings ratio: Ultragenyx Pharmaceutical Inc. lost $5.19 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Ultragenyx Pharmaceutical Inc. make?
Ultragenyx Pharmaceutical Inc. generated revenue of $730.00M over the trailing twelve months, which puts the stock at 2.26 times sales.
What is the 52-week range for RARE?
RARE has traded between $12.73 and $39.89 over the past 52 weeks, and the last price is 58.1% below that high.
Is Ultragenyx Pharmaceutical Inc. profitable?
No. Ultragenyx Pharmaceutical Inc. is loss-making, with a net margin of -71.78% over the trailing twelve months.
What is the analyst price target for RARE?
Wall Street analysts rate RARE Buy, with an average price target of $25.54, 52.9% above the current price.
What sector is Ultragenyx Pharmaceutical Inc. in?
Ultragenyx Pharmaceutical Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Ultragenyx Pharmaceutical Inc.?
Emil D. Kakkis is the chief executive of Ultragenyx Pharmaceutical Inc., which employs 1,371 people.
Where can I track RARE in real time?
QFI Terminal shows RARE with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See RARE live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open RARE in Terminal See plans